Dimethyl fumarate Mylan Európai Unió - magyar - EMA (European Medicines Agency)

dimethyl fumarate mylan

mylan ireland limited - dimetil-fumarát - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Accord Európai Unió - magyar - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - dimetil-fumarát - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Neuraxpharm Európai Unió - magyar - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetil-fumarát - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Polpharma Európai Unió - magyar - EMA (European Medicines Agency)

dimethyl fumarate polpharma

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetil-fumarát - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Teva Európai Unió - magyar - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dimetil-fumarát - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Teysuno Európai Unió - magyar - EMA (European Medicines Agency)

teysuno

nordic group b.v. - tegafur, gimeracil, oteracil - gyomor-daganatok - daganatellenes szerek - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.